Deutsche Bank out positive on BioMimetic Therapeutics (NASDAQ:BMTI) saying they conducted a due diligence call with Dr. Jeffrey Wieman, the Lead Investigator for the Regranex pivotal study and involved with the product since its preclinical days, to discuss recent concerns over potential Regranex cancer deaths. Based on all his work with Regranex, Dr. Weiman does not believe there is a causal relationship between Regranex (or PDGF) and carcinogenesis/cancer deaths.
Also, he is actually a cancer expert and CEO of St. Luke's Cancer Institute (Univ. of Missouri) and understands the nuances of cancer mechanism/science.
Firm continues to believe FDA's Regranex safety review will not materially impact BMTI's GEM OS1 clinical/regulatory outlook given the poor clinical/scientific link between recombinant PDGF and cancer.
Reiterates Buy and $22 target.
Notablecalls: You gotta buy BMTI here. Based on DB's call the stock deserves to trade around $11-$12 here. Going to call it an Actionable Trading Call.